Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Purchased by Chase Investment Counsel Corp

Chase Investment Counsel Corp raised its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 45.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,000 shares of the company’s stock after acquiring an additional 9,000 shares during the quarter. Chase Investment Counsel Corp owned 0.06% of Amphastar Pharmaceuticals worth $1,407,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Victory Capital Management Inc. increased its stake in Amphastar Pharmaceuticals by 10.9% during the 3rd quarter. Victory Capital Management Inc. now owns 218,531 shares of the company’s stock worth $10,605,000 after buying an additional 21,530 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Amphastar Pharmaceuticals during the third quarter worth about $303,000. Los Angeles Capital Management LLC purchased a new stake in Amphastar Pharmaceuticals during the 3rd quarter worth approximately $785,000. Assetmark Inc. boosted its stake in Amphastar Pharmaceuticals by 9.1% during the 3rd quarter. Assetmark Inc. now owns 43,906 shares of the company’s stock valued at $2,131,000 after acquiring an additional 3,650 shares during the last quarter. Finally, AlphaCentric Advisors LLC grew its holdings in Amphastar Pharmaceuticals by 20.0% during the 3rd quarter. AlphaCentric Advisors LLC now owns 30,000 shares of the company’s stock worth $1,456,000 after acquiring an additional 5,000 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Price Performance

AMPH opened at $47.71 on Wednesday. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The company’s 50-day moving average price is $48.45 and its 200 day moving average price is $44.34. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $36.56 and a fifty-two week high of $65.92. The firm has a market cap of $2.29 billion, a price-to-earnings ratio of 15.90, a price-to-earnings-growth ratio of 0.94 and a beta of 0.82.

Insider Transactions at Amphastar Pharmaceuticals

In related news, Director Floyd F. Petersen sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $46.47, for a total transaction of $139,410.00. Following the completion of the transaction, the director now owns 75,409 shares in the company, valued at $3,504,256.23. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 7,426 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $386,523.30. Following the sale, the chief financial officer now owns 94,103 shares in the company, valued at approximately $4,898,061.15. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Floyd F. Petersen sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $46.47, for a total value of $139,410.00. Following the transaction, the director now owns 75,409 shares of the company’s stock, valued at approximately $3,504,256.23. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 19,640 shares of company stock worth $990,722. 27.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on AMPH shares. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Piper Sandler cut their price objective on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Finally, StockNews.com lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $63.00.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.